Why the study?
Does pharmacological modulation of ERK1/2 and p38-MAPK pathways alter the inotropic effect of endothelin-1 in isolated perfused rat hearts?
Does pharmacological modulation of ERK1/2 and p38-MAPK pathways alter the inotropic effect of endothelin-1 in isolated perfused rat hearts?
ERK1/2 mediates a positive inotropic response to ET-1 that is counterbalanced by p38-MAPK, suggesting that selective modulation of these pathways could support cardiac contractility.
Hypothesis-generating in rat hearts; leaves open whether selective ERK1/2 or p38-MAPK modulation can enhance contractility in human HF.
No takes yet. Share an insight, caveat, or question.
Szokodi et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: